Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1070806 in Moderate-to-Severe Atopic Dermatitis (Phase II)
CTR20240627Phase 2Terminated
- Sponsor
- GSK
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of aletekitug in atopic dermatitis (AD), sponsored by GSK. Started Mar 2024; status: terminated.
02
Drugs
aletekitug
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20240627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240627.